Latanoprost niosomes as a sustained release ocular delivery system for the management of glaucoma

References

• Sun X, Dai Y, Chen Y, et al. Primary angle closure glaucoma: what we know and what we don’t know. Prog Retin Eye Res. 2017;57:26–45.
   PubMed Web of Science ®Google Scholar
• Coleman AL, Miglior S. Risk factors for glaucoma onset and progression. Surv Ophthalmol. 2008;53(6):S3–S10.
   PubMed Web of Science ®Google Scholar
• Actis AG, Dall'Orto L, Penna R, et al. An internal medicine perspective review of risk factors for assessing and progression of primary open angle glaucoma. Minerva Med. 2013;104(4):471–485.
   PubMed Web of Science ®Google Scholar
• Sambhara D, Aref AA. Glaucoma management: relative value and place in therapy of available drug treatments. Ther Adv Chronic Dis. 2014;5(1):30–43.
   PubMedGoogle Scholar
• Bettin P, Di Matteo F. Glaucoma: present challenges and future trends. Ophthalmic Res. 2013;50(4):197–208.
   PubMed Web of Science ®Google Scholar
• van der Valk R, Webers CAB, Schouten J, et al. Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials. Ophthalmology. 2005;112(7):1177–1185.
   PubMed Web of Science ®Google Scholar
• Alm A. Latanoprost in the treatment of glaucoma. Clin Ophthalmol. 2014;8:1967–1985.
   PubMedGoogle Scholar
• Sjöquist B, Stjernschantz J. Ocular and systemic pharmacokinetics of latanoprost in humans. Surv Ophthalmol. 2002;47(Suppl. 1):S6–S12.
   PubMed Web of Science ®Google Scholar
• Xiang CD, Batugo M, Gale DC, et al. Characterization of human corneal epithelial cell model as a surrogate for corneal permeability assessment: metabolism and transport. Drug Metab Dispos. 2009;37(5):992–998.
   PubMed Web of Science ®Google Scholar
• Giarmoukakis A, Labiris G, Sideroudi H, et al. Biodegradable nanoparticles for controlled subconjunctival delivery of latanoprost acid: in vitro and in vivo evaluation. Preliminary results. Exp Eye Res. 2013;112:29–36.
   PubMed Web of Science ®Google Scholar
• Natarajan JV, Chattopadhyay S, Ang M, et al. Sustained release of an anti-glaucoma drug: demonstration of efficacy of a liposomal formulation in the rabbit eye. PLoS One. 2011;6(9):E24513.
   PubMed Web of Science ®Google Scholar
• Fathalla D, Soliman GM, Fouad E. Development and in vitro/in vivo evaluation of liposomal gels for the sustained ocular delivery of latanoprost. J Clin Exp Ophthalmol. 2015;6(390):2.
   Google Scholar
• Natarajan JV, Ang M, Darwitan A, et al. Nanomedicine for glaucoma: liposomes provide sustained release of latanoprost in the eye. Int J Nanomed. 2012;7:123–131.
   PubMed Web of Science ®Google Scholar
• Ali J, Fazil M, Qumbar M, et al. Colloidal drug delivery system: amplify the ocular delivery. Drug Deliv. 2016;23(3):700–726.
   Web of Science ®Google Scholar
• Eid RK, Essa EA, El Maghraby GM. Essential oils in niosomes for enhanced transdermal delivery of felodipine. Pharm Dev Technol. 2019;24(2):157–165.
   PubMed Web of Science ®Google Scholar
• Gaafar PM, Abdallah OY, Farid RM, et al. Preparation, characterization and evaluation of novel elastic nano-sized niosomes (ethoniosomes) for ocular delivery of prednisolone. J Liposome Res. 2014;24(3):204–215.
   PubMed Web of Science ®Google Scholar
• Gershkovich P, Wasan KM, Barta CA. A review of the application of lipid-based systems in systemic, dermal/transdermal, and ocular drug delivery. Crit Rev Ther Drug Carrier Syst. 2008;25(6):545–584.
   PubMed Web of Science ®Google Scholar
• Honda M, Asai T, Oku N, et al. Liposomes and nanotechnology in drug development: focus on ocular targets. Int J Nanomed. 2013;8:495–503.
   PubMed Web of Science ®Google Scholar
• Abdelbary A, Salem HF, Khallaf RA, et al. Mucoadhesive niosomal in situ gel for ocular tissue targeting: in vitro and in vivo evaluation of lomefloxacin hydrochloride. Pharm Dev Technol. 2017;22(3):409–417.
   PubMed Web of Science ®Google Scholar
• Abdelbary G, El-Gendy N. Niosome-encapsulated gentamicin for ophthalmic controlled delivery. AAPS PharmSciTech. 2008;9(3):740–747.
   PubMed Web of Science ®Google Scholar
• Nasr M, Mansour S, Mortada ND, et al. Vesicular aceclofenac systems: a comparative study between liposomes and niosomes. J Microencapsul. 2008;25(7):499–512.
   PubMed Web of Science ®Google Scholar
• Gan L, Wang J, Jiang M, et al. Recent advances in topical ophthalmic drug delivery with lipid-based nanocarriers. Drug Discov Today. 2013;18(5–6):290–297.
   PubMed Web of Science ®Google Scholar
• Guinedi AS, Mortada ND, Mansour S, et al. Preparation and evaluation of reverse-phase evaporation and multilamellar niosomes as ophthalmic carriers of acetazolamide. Int J Pharm. 2005;306(1–2):71–82.
   PubMed Web of Science ®Google Scholar
• Hathout RM, Mansour S, Mortada ND, et al. Liposomes as an ocular delivery system for acetazolamide: in vitro and in vivo studies. AAPS PharmSciTech. 2007;8(1):E1–E12.
   PubMed Web of Science ®Google Scholar
• Schmolka IR. Artificial skin. I. Preparation and properties of pluronic F-127 gels for treatment of burns. J Biomed Mater Res. 1972;6(6):571–582.
   PubMed Web of Science ®Google Scholar
• Ameeduzzafar , Ali J, Bhatnagar A, et al. Chitosan nanoparticles amplify the ocular hypotensive effect of cateolol in rabbits. Int J Biol Macromol. 2014;65:479–491.
   PubMed Web of Science ®Google Scholar
• Aksungur P, Demirbilek M, Denkbaş EB, et al. Development and characterization of cyclosporine A loaded nanoparticles for ocular drug delivery: cellular toxicity, uptake, and kinetic studies. J Control Release. 2011;151(3):286–294.
   PubMed Web of Science ®Google Scholar
• Costa P, Sousa Lobo JM. Modeling and comparison of dissolution profiles. Eur J Pharm Sci. 2001;13(2):123–133.
   PubMed Web of Science ®Google Scholar
• Liu Z, Nie S, Guo H, et al. Effects of transcutol P on the corneal permeability of drugs and evaluation of its ocular irritation of rabbit eyes. J Pharm Pharmacol. 2006;58(1):45–50.
   PubMed Web of Science ®Google Scholar
• Baeyens V, Felt-Baeyens O, Rougier S, et al. Clinical evaluation of bioadhesive ophthalmic drug inserts (BODI) for the treatment of external ocular infections in dogs. J Control Release. 2002;85(1–3):163–168.
   PubMed Web of Science ®Google Scholar
• Mishra V, Jain NK. Acetazolamide encapsulated dendritic nano-architectures for effective glaucoma management in rabbits. Int J Pharm. 2014;461(1–2):380–390.
   PubMed Web of Science ®Google Scholar
• Kaur IP, Singh M, Kanwar M. Formulation and evaluation of ophthalmic preparations of acetazolamide. Int J Pharm. 2000;199(2):119–127.
   PubMed Web of Science ®Google Scholar
• Kumar GP, Rajeshwarrao P. Nonionic surfactant vesicular systems for effective drug delivery—an overview. Acta Pharm Sin B. 2011;1(4):208–219.
   Web of Science ®Google Scholar
• Paul S, Mondol R, Ranjit S, et al. Antiglaucomatic niosomal system: recent trend in ocular drug delivery research. Int J Pharm Pharm Sci. 2010;2:15–18.
   Google Scholar
• Hunter CA, Dolan TF, Coombs GH, et al. Vesicular systems (niosomes and liposomes) for delivery of sodium stibogluconate in experimental murine visceral leishmaniasis. J Pharm Pharmacol. 1988;40(3):161–165.
   PubMed Web of Science ®Google Scholar
• Deniz A, Sade A, Severcan F, et al. Celecoxib-loaded liposomes: effect of cholesterol on encapsulation and in vitro release characteristics. Biosci Rep. 2010;30(5):365–373.
   PubMed Web of Science ®Google Scholar
• El-Samaligy MS, Afifi NN, Mahmoud EA. Increasing bioavailability of silymarin using a buccal liposomal delivery system: preparation and experimental design investigation. Int J Pharm. 2006;308(1–2):140–148.
   PubMed Web of Science ®Google Scholar
• Esaki N, Pipkin JD, inventors; CyDeX Pharmaceuticals, Inc., assignee. Composition containing sulfoalkyl ether cyclodextrin and latanoprost. United States patent US 20,120,021,013 A1. 2012 Jan 26.
   Google Scholar
• Rojanapanthu P, Sarisuta N, Chaturon K, et al. Physicochemical properties of amphotericin B liposomes prepared by reverse-phase evaporation method. Drug Dev Ind Pharm. 2003;29(1):31–37.
   PubMed Web of Science ®Google Scholar
• Ning M, Guo Y, Pan H, et al. Niosomes with sorbitan monoester as a carrier for vaginal delivery of insulin: studies in rats. Drug Deliv. 2005;12(6):399–407.
   PubMed Web of Science ®Google Scholar
• Hao Y, Zhao F, Li N, et al. Studies on a high encapsulation of colchicine by a niosome system. Int J Pharm. 2002;244(1–2):73–80.
   PubMed Web of Science ®Google Scholar
• Manosroi A, Wongtrakul P, Manosroi J, et al. Characterization of vesicles prepared with various non-ionic surfactants mixed with cholesterol. Colloids Surf B Biointerfaces. 2003;30(1–2):129–138.
   Web of Science ®Google Scholar
• Lu XY, Wu DC, Li ZJ, et al. Polymer nanoparticles. Prog Mol Biol Transl Sci. 2011;104:299–323.
   PubMed Web of Science ®Google Scholar
• Sikkandar S, Jayakumar S, Gunasekaran S, et al. Study on the analysis of human gallstones using Fourier transform infrared spectroscopic technique. Int J ChemTech Res. 2011;3:149–154.
   Google Scholar
• Mourtas S, Fotopoulou S, Duraj S, et al. Liposomal drugs dispersed in hydrogels: effect of liposome, drug and gel properties on drug release kinetics. Colloids Surf B Biointerfaces. 2007;55(2):212–221.
   PubMed Web of Science ®Google Scholar
• Ritger PL, Peppas NA. A simple equation for description of solute release. II. Fickian and anomalous release from swellable devices. J Control Release. 1987;5(1):37–42.
   Google Scholar
• Roggeband R, York M, Pericoi M, et al. Eye irritation responses in rabbit and man after single applications of equal volumes of undiluted model liquid detergent products. Food Chem Toxicol. 2000;38(8):727–734.
   PubMed Web of Science ®Google Scholar
• Soliman GM, Fetih G, Abbas AM. Thermosensitive bioadhesive gels for the vaginal delivery of sildenafil citrate: in vitro characterization and clinical evaluation in women using clomiphene citrate for induction of ovulation. Drug Dev Ind Pharm. 2017;43(3):399–408.
   PubMed Web of Science ®Google Scholar
• Harasymowycz P, Hutnik CML, Nicolela M, et al. Latanoprost versus timolol gel-forming solution once daily in primary open-angle glaucoma or ocular hypertension. Can J Ophthalmol. 2007;42(1):75–81.
   PubMed Web of Science ®Google Scholar
• Kim NJ, Harris A, Gerber A, et al. Nanotechnology and glaucoma: a review of the potential implications of glaucoma nanomedicine. Br J Ophthalmol. 2014;98(4):427–431.
   PubMed Web of Science ®Google Scholar